Portal de Periódicos da CAPES

Initial results of the quanam drug eluting stent (QuaDS‐QP‐2) registry (BARDDS) in human subjects

2001; Wiley; Volume: 53; Issue: 4 Linguagem: Inglês

10.1002/ccd.1207

1522-726X

Luís de la Fuente, Jorge Miano, Jorge Mrad, Eduardo Peñaloza, Alan C. Yeung, Robert Eury, Michael Froix, Peter J. Fitzgerald, Simon H. Stertzer,

Integrated Circuits and Semiconductor Failure Analysis

Thirty-two patients presenting with varied coronary syndromes and anatomy were treated with a new coronary multisleeve drug delivery coronary stent (QuaDS-QP-2) containing up to 4,000 microg of a taxol-derived lipophilic microtubule inhibitor (QP2). The device was successfully implanted in 32 patients who have been followed for up to 2 years. Twenty-five patients have undergone stress ECHO or SPECT Thallium and all are currently asymptomatic. Thirteen patients have already been restudied angiographically, by IVUS and/or by SPECT Thallium testing and are detailed in this report. Angiographic, IVUS, and SPECT Thallium have been controlled at a mean of 11.2 months (range, 6-15 months) in this 13-patient cohort. Although all 13 QuaDS-QP-2 (QDES) stents were angiographically and IVUS patent, two reinterventions have been required in the 32-patient study group thus far, both relate to either new disease or to distal, small-vessel disease beyond the stent. There was no evidence of significant proliferation in the QDES devices. On the basis of this preliminary data and a European pilot study, a controlled randomized trial (SCORE) is currently in progress in western Europe.